Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine

• Published in: AIDS research and therapy Vol. 21; no. 1; pp. 1 - 6
• Main Authors: Adachi, Eisuke, Saito, Makoto, Otani, Amato, Koga, Michiko, Yotsuyanagi, Hiroshi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.01.2024; BioMed Central; BMC
• Subjects: Acquired immune deficiency syndrome; AIDS; Analysis; Analysis and chemistry; Anti-HIV Agents - therapeutic use; Anti-Retroviral Agents - therapeutic use; Antiretroviral drugs; Antiviral agents; Biological markers; Biomarkers; Blood; Blood cholesterol; C-reactive protein; Cabotegravir plus rilpivirine; CD4 antigen; CD8 antigen; Cholesterol; Cholesterol - therapeutic use; Clinical medicine; Clinical trials; Density; Dosage and administration; Drug dosages; Health aspects; High density lipoprotein; HIV; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Inflammation; Inflammatory biomarker; Inflammatory diseases; Lipid profile; Lipids; Long-acting drug; Low density lipoproteins; Measurement; Raltegravir; Rilpivirine; Rilpivirine - therapeutic use; Switching; Tenofovir; Variance analysis; Japan; Cabotegravir plus rilpivirine; Lipid profile; Long-acting drug; HIV; Inflammatory biomarker

We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. Th...